Empirical Financial Services LLC d.b.a. Empirical Wealth Management Has $1.92 Million Stake in Edwards Lifesciences Corporation $EW

Empirical Financial Services LLC d.b.a. Empirical Wealth Management decreased its holdings in Edwards Lifesciences Corporation (NYSE:EW) by 0.9% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 24,516 shares of the medical research company’s stock after selling 217 shares during the period. Empirical Financial Services LLC d.b.a. Empirical Wealth Management’s holdings in Edwards Lifesciences were worth $1,917,000 as of its most recent SEC filing.

Several other large investors have also made changes to their positions in EW. Brighton Jones LLC bought a new stake in shares of Edwards Lifesciences in the 4th quarter valued at approximately $266,000. Merit Financial Group LLC grew its stake in shares of Edwards Lifesciences by 93.4% in the 1st quarter. Merit Financial Group LLC now owns 10,793 shares of the medical research company’s stock valued at $782,000 after buying an additional 5,212 shares in the last quarter. Unique Wealth LLC bought a new stake in shares of Edwards Lifesciences in the 1st quarter valued at approximately $248,000. Ehrlich Financial Group grew its stake in shares of Edwards Lifesciences by 5.7% in the 1st quarter. Ehrlich Financial Group now owns 10,950 shares of the medical research company’s stock valued at $794,000 after buying an additional 586 shares in the last quarter. Finally, Radnor Capital Management LLC grew its stake in shares of Edwards Lifesciences by 11.1% in the 1st quarter. Radnor Capital Management LLC now owns 24,070 shares of the medical research company’s stock valued at $1,745,000 after buying an additional 2,400 shares in the last quarter. Institutional investors own 79.46% of the company’s stock.

Edwards Lifesciences Stock Up 0.5%

EW opened at $77.03 on Friday. Edwards Lifesciences Corporation has a 1-year low of $64.00 and a 1-year high of $83.00. The company has a current ratio of 4.68, a quick ratio of 3.87 and a debt-to-equity ratio of 0.06. The stock has a market capitalization of $45.22 billion, a price-to-earnings ratio of 11.08, a P/E/G ratio of 3.69 and a beta of 1.05. The business has a 50 day moving average of $78.50 and a 200-day moving average of $75.94.

Edwards Lifesciences (NYSE:EW) last posted its quarterly earnings data on Thursday, July 24th. The medical research company reported $0.67 earnings per share for the quarter, beating the consensus estimate of $0.62 by $0.05. Edwards Lifesciences had a return on equity of 15.01% and a net margin of 72.96%.The company had revenue of $1.53 billion during the quarter, compared to analysts’ expectations of $1.49 billion. During the same period in the prior year, the business earned $0.70 earnings per share. Edwards Lifesciences’s revenue for the quarter was up 11.9% compared to the same quarter last year. Edwards Lifesciences has set its Q3 2025 guidance at 0.540-0.60 EPS. FY 2025 guidance at 2.400-2.500 EPS. As a group, sell-side analysts anticipate that Edwards Lifesciences Corporation will post 2.45 earnings per share for the current year.

Analysts Set New Price Targets

EW has been the subject of several recent research reports. JPMorgan Chase & Co. boosted their price target on Edwards Lifesciences from $80.00 to $85.00 and gave the company a “neutral” rating in a research note on Friday, July 25th. Piper Sandler upped their target price on Edwards Lifesciences from $83.00 to $90.00 and gave the stock an “overweight” rating in a research report on Friday, July 25th. Deutsche Bank Aktiengesellschaft upped their target price on Edwards Lifesciences from $85.00 to $94.00 and gave the stock a “buy” rating in a research report on Friday, July 25th. Daiwa America raised Edwards Lifesciences from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, July 29th. Finally, Royal Bank Of Canada upped their target price on Edwards Lifesciences from $85.00 to $89.00 and gave the stock an “outperform” rating in a research report on Friday, July 25th. Three analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, nine have issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $86.61.

Insider Activity at Edwards Lifesciences

In related news, VP Daniel J. Lippis sold 4,114 shares of the company’s stock in a transaction on Monday, July 28th. The stock was sold at an average price of $79.46, for a total value of $326,898.44. Following the completion of the transaction, the vice president directly owned 22,002 shares in the company, valued at approximately $1,748,278.92. This represents a 15.75% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Larry L. Wood sold 8,950 shares of the company’s stock in a transaction on Monday, August 18th. The shares were sold at an average price of $78.06, for a total value of $698,637.00. Following the completion of the transaction, the insider owned 206,900 shares of the company’s stock, valued at $16,150,614. The trade was a 4.15% decrease in their ownership of the stock. The disclosure for this sale can be found here. 1.29% of the stock is currently owned by corporate insiders.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.